RINVOQ、Rematib、upanib、乌帕替尼

Upadacitinib

Another Name
RINVOQ、Rematib、upanib、乌帕替尼
Indications
Upadacitinib can regulate abnormal immune responses, alleviate inflammation and symptoms of diseases.
Reg No
04 L 1091/24
Inspection No
0668-24
dosage form:tablets
Specs:15mg*30tablets
Indate:24 months
Date：2024-9-1 Views：1260
Drug Info

COMPOSITION:

Each film-coated tablet contains Upadacitinib… 15 mg.

INDICATION:

LuciUpa is a Janus kinase (JAK) inhibitor indicated for the treatment of:

• Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

• Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.

• Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.

DOSAGE AND USE:

• Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis the recommended dosage is 15 mg once daily.

• Ulcerative Colitis the recommended induction dosage is 45 mg once daily for 8 weeks. The recommended maintenance dosage is 15 mg once daily.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciUpa during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/upadacitinib/

Related News